GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (OTCPK:AVHHL) » Definitions » EV-to-EBITDA

AVITA Medical (AVITA Medical) EV-to-EBITDA : -5.34 (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AVITA Medical's enterprise value is $179.10 Mil. AVITA Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-33.54 Mil. Therefore, AVITA Medical's EV-to-EBITDA for today is -5.34.

The historical rank and industry rank for AVITA Medical's EV-to-EBITDA or its related term are showing as below:

AVHHL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -260.22   Med: -10.44   Max: -1.04
Current: -5.34

During the past 13 years, the highest EV-to-EBITDA of AVITA Medical was -1.04. The lowest was -260.22. And the median was -10.44.

AVHHL's EV-to-EBITDA is ranked worse than
100% of 484 companies
in the Medical Devices & Instruments industry
Industry Median: 16.065 vs AVHHL: -5.34

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), AVITA Medical's stock price is $1.53. AVITA Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.280. Therefore, AVITA Medical's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


AVITA Medical EV-to-EBITDA Historical Data

The historical data trend for AVITA Medical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical EV-to-EBITDA Chart

AVITA Medical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -115.36 -14.06 -15.54 -3.38 -9.11

AVITA Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.38 -10.94 -12.32 -9.58 -9.11

Competitive Comparison of AVITA Medical's EV-to-EBITDA

For the Medical Devices subindustry, AVITA Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AVITA Medical's EV-to-EBITDA falls into.



AVITA Medical EV-to-EBITDA Calculation

AVITA Medical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=179.100/-33.54
=-5.34

AVITA Medical's current Enterprise Value is $179.10 Mil.
AVITA Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVITA Medical  (OTCPK:AVHHL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

AVITA Medical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.53/-0.280
=At Loss

AVITA Medical's share price for today is $1.53.
AVITA Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.280.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


AVITA Medical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AVITA Medical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AVITA Medical (AVITA Medical) Business Description

Traded in Other Exchanges
Address
28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.